A carregar...
Targeting opioid dysregulation in depression for the development of novel therapeutics
Since the serendipitous discovery of the first class of modern antidepressants in the 1950’s, all pharmacotherapies approved by the Food and Drug Administration for major depressive disorder (MDD) have shared a common mechanism of action, increased monoaminergic neurotransmission. Despite the widesp...
Na minha lista:
| Publicado no: | Pharmacol Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6859062/ https://ncbi.nlm.nih.gov/pubmed/31051197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2019.04.009 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|